Opinion

Video

Future Directions in mCRPC

Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.

Related Videos
1 expert in this video
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.